剖宫产术同时核出子宫肌瘤患者临床及预后分析

Clinical Prognosis of Patients Receiving Myomectomy during Cesarean Section

目的探讨剖宫产术同时子宫肌瘤核出的可行性及术后复发情况。方法对2005年1月—2007年12月于北京友谊医院剖宫产术同时行子宫肌瘤核出的122例患者临床资料及术后随访情况进行回顾性分析。3年间分娩总数为5199例,剖宫产术同时行子宫肌瘤核出122例,占分娩总数的2.36%;术中平均出血(186±52)ml。结果 122例剖宫产术同时行子宫肌瘤核出的患者中随访到82例,随访2～4年,6例复发,复发率7.32%;复发时间为术后1.1～3.5年,1例再次手术。结论剖宫产术同时核出子宫肌瘤安全可行,剖宫产术同时核出肌瘤术后复发率明显低于非妊娠妇女术后复发率。但处在生育期妇女术后应定期复查,以便及时了解肌瘤复发情况,掌握治疗时机,减少手术机会及早发现肌瘤并发症。

Objective To summarize the clinical prognosis of myomectomy during cesarean section.Methods The clinical data of 122 pregnant women （2.36% of total delivery） who had undergone myomectomy during cesarean section between January 2005 and December 2007 were retrospectively analyzed.Results The average intraoperative blood loss was（186±52）ml.Follow-up was completed in 82 of 122 patients for 2～4 years.Tumors recurred in 6 patients （7.32%） 1.1～3.5 years after operation.One patient received a second operation.Conclusion Elective myomectomy during cesarean section is a feasible and safe;however,more follow-up should be performed to understand recurrence among these patients.